Lipidor (LIPI.ST) Stock Analysis & AI Equity Report
Lipidor (LIPI.ST) overview
Lipidor (LIPI.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Lipidor reported revenue of SEK 0.0m and operating profit of SEK -14.2m; the year-end share price was 0.21 SEK and market capitalisation was SEK 92.1m. Lipidor is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lipidor's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-10-15. Data will be refreshed during report generation.
About Lipidor
Lipidor AB is a Swedish pharmaceutical development company focused on topical treatments for skin diseases. It develops drug candidates through its patented AKVANO formulation technology, reformulating established active substances into sprayable, fast-drying medicines for conditions including psoriasis, acne, bacterial skin infections, and atopic dermatitis. Its lead project is AKP02G2 for psoriasis.
Generate the Lipidor report
Lipidor is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Lipidor and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.